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Abstract 
Management of invasive aspergillosis in high risk patients remains a challenging effort. There 
is an increasing demand for novel therapeutic strategies aiming at enhancing or restoring 
antifungal immunity in immunocompromised patients. In this regard, modulating specific 
innate immune functions and vaccination are promising immunotherapeutic strategies. Recent 
findings have also provided a compelling rationale to assess the contribution of the individual 
genetic profile to the immunotherapy outcome. Altogether, integrating immunologic and 
genetic data may contribute to the optimization of therapeutic strategies exerting control over 
immune pathways, ultimately improving the management of fungal infections in high risk 
settings. 
 
 
Aspergillus fumigatus is a ubiquitous mould that can adapt to a broad range of environmental 
conditions [1].  A. fumigatus can cause a number of diseases ranging from allergic to invasive, 
life-threatening forms of infection, which are strictly defined by the immune status of the 
host. The more severe forms of aspergillosis occur in specific clinical settings such as patients 
with hematological malignancies and prolonged and severe neutropenia, or patients on 
corticosteroid therapy and solid organ or stem cell transplantation. Management of invasive 
aspergillosis in high risk settings remains challenging due to intrinsic or acquired antifungal 
resistance, organ dysfunction preventing the use of particular agents and the deleterious 
effects of deregulated inflammation. Thus, there is an ever-increasing demand for novel 
therapeutic strategies to enhance or restore critical immune functions that may be applied to 
patients at high risk for fungal infections [1]. 
This review will highlight the conceptual advances made in cellular and 
immunological mechanisms underlying the host-fungus interaction and how this knowledge 
may be exploited for the successful design of immunotherapeutic interventions. The 
pathophysiology mechanisms underlying susceptibility to invasive aspergillosis are 
highlighted along with the awareness that the genetic make-up of the host may also critically 
contributes to risk for this disease [2-3]. 
 
  
Immunology of aspergillosis: from innate to adaptive immune responses 
In the absence of major immune deficiencies, humans are relatively resistant to infection by 
A. fumigatus due to the immunological inertia of resting conidia [4]. This also implies that for 
most healthy humans, innate immune mechanisms are sufficient to clear the organism. These 
include the physical barriers of the respiratory tract and the activation of cellular [alveolar 
macrophages, dendritic cells (DCs) and recruited neutrophils] and humoral [pentraxin (PTX) 
3 (see below), complement and cytokines] effector mechanisms of innate immunity (reviewed 
in [1]). Germination, however, exposes fungal-specific carbohydrates that serve as targets for 
invariant, germline-encoded pattern recognition receptors (PRRs)—such as Toll-like 
receptors (TLRs) and C-type lectin receptors— that are crucial for the initiation of innate and 
adaptive T helper (Th) immune responses [5]. Generation of a dominant Th1 response is 
essentially required for the expression of protective immunity to the fungus. Through the 
production of the signature cytokine IFN-γ, Th1 cells are instrumental for an optimal 
microbicidal activity of phagocytes. In contrast, allergic manifestations following inhalation 
of conidia due to overzealous Th2 responses are classical examples of the pathogenic role of 
T cell dysreactivity in fungal diseases. However, a further degree of complexity of cross-
regulatory innate and adaptive Th pathways lies beyond the dichotomous Th1/Th2 model. 
Recent insights have suggested a role for Th17 cells, as a link between T cell inflammation 
and granulocytic influx observed in allergic airway inflammation [5]. The Th17 pathway, 
playing an inflammatory role previously attributed to uncontrolled Th1 cell reactivity and 
regulatory T cells (Tregs), capable of fine-tuning protective antimicrobial immunity in order 
to minimize harmful immune pathology, are now regarded as integral components of the 
immune response to the fungus (figure 1). The enzyme indoleamine 2,3–dioxygenase (IDO) 
and kynurenines pivotally contribute to this delicate balance by providing the host with 
immune mechanisms adequate for protection without necessarily eliminating fungal 
pathogens or causing an unacceptable level of tissue damage (see below). Specific antibodies 
to A. fumigatus have also been successfully detected in patients suffering from invasive 
aspergillosis, and their role in infection could be of interest. Indeed, a glyco-conjugate vaccine 
was found to efficiently immunize and protect mice against the  infection [6], suggesting a 
role for antibody-mediated protection in aspergillosis. 
 
  
Aspergillosis as an example of inflammatory disease 
Although the inflammatory response to fungi may serve to limit infection, an overzealous or 
heightened inflammatory response may contribute to pathogenicity. This conceptual principle 
is best exemplified by the occurrence of severe fungal infections in patients with 
immunoreconstitution syndrome (IRS), an entity characterized by localized and systemic 
inflammatory reactions of varying degrees that have both beneficial and deleterious effects to 
the host [7]. Intriguingly, IRS responses are found after rapid resolution of 
immunosuppression, indicating that inflammatory responses can result in quiescent or latent 
infections manifesting as opportunistic mycoses. Thus, although host immunity is crucial in 
eradicating infection, immunological recovery can also be detrimental and may contribute 
towards worsening disease in opportunistic and non-opportunistic infections [7]. The 
association of persistent inflammation with intractable Aspergillus infection is common in 
non-neutropenic patients after allogeneic hematopoietic stem cell transplantation and in the 
hyper-IgE syndrome  in which increased levels of pro-inflammatory gene transcripts have 
been described [8]. Therefore, the status of innate host immunity may contribute significantly 
to the pattern of diseases associated with fungal exposure. Corroborating these findings, 
recent works highlight the role of sterile inflammation – that is, (auto)inflammation caused by 
endogenous ligands – as a pathogenic determinant responsible for inflammation-driven 
pathology in aspergillosis [9]. Most prominently, in patients with chronic granulomatous 
disease (CGD), a hyperinflammatory phenotype and defective fungal—typically A. 
fumigatus—clearance have long been known to occur. This condition is crucially exemplified 
by recent findings in CGD mice, in which an intrinsic, genetically determined failure to 
control inflammation to sterile fungal components determines the animals’ inability to resolve 
an actual infection with A. fumigatus [10]. These observations highlight a truly bipolar nature 
of the inflammatory process in infection. Early inflammation prevents or limits infection, but 
an uncontrolled response may eventually oppose disease eradication. A main implication of 
these findings is that, at least in specific clinical settings, it is an exaggerated inflammatory 
response that likely compromises a patient’s ability to eradicate infection, and not an 
‘intrinsic’ susceptibility to infection that determines a state of chronic or intractable disease.  
 
  
Translating immunity into clinical perspectives 
Colony stimulating factors (CSFs), granulocyte transfusions and cytokines. CSFs and 
cytokines, mainly IFN-γ, have been utilized in the clinical management of fungal diseases 
[11]. CSFs and granulocyte transfusions are used to augment the number and the function 
of circulating neutrophils in neutropenic patients. Studies in vitro, in animal models and 
limited patient data provide a rationale for adjunctive IFN-γ for invasive aspergillosis. The 
limited clinical experience to date shows a possible benefit of these cytokines, and further 
controlled clinical trials are needed to validate their routine use in cancer patients and stem-
cell transplant recipients with invasive fungal infections who are likely to have a poor 
response to antifungal drug therapy [12]. Pairing IFN-γ with CSFs could be an option in the 
setting of refractory fungal disease, although clinical experience is anecdotal and the 
efficacy of this approach is not established (reviewed in [13]). Moreover, the disparate 
activity of CSFs on the immune system and types of immune responses generated, would 
suggest an activity for CSFs beyond their effects on hematopoiesis [14]. For instance, 
granulocyte-macrophage (GM)-CSF has recently been shown to play a key role in human 
DCs for activation of inflammatory Th1 and Th17 cells, and served a nonredundant 
function in the initiation of autoimmune inflammation [15]. Emerging evidence 
demonstrates the benefits of granulocyte transfusions to treat infections in patients after 
treatment with high-dose chemotherapy, particularly the chemotherapy associated with 
conditioning for hematopoietic stem cell transplant. The increased interest in the use of 
therapeutic granulocyte transfusion in recent years stems largely from improvements in 
donor mobilization methods. However, the evidence for clinical efficacy is limited to that 
of case reports and small series, and the results are not uniform. Randomized controlled 
clinical trials are needed to determine whether this therapy is useful in either clearing 
infections or prolonging survival [16-17]. 
T-cell therapy. T cell-mediated heterologous immunity to different pathogens is promising 
for the development of immunotherapeutic strategies. Fungus-specific CD4+ Th1 immunity 
is an appealing strategy for antifungal therapy [18]. Recently, an immunogenic epitope of 
the A. fumigatus cell wall glucanase Crf1 was described as capable of inducing major 
histocompatibility complex class II restricted memory CD4+ Th1 cells that are cross-
reactive with C albicans [19]. These data illustrate the existence of T cell-based cross-
protection for the distantly related clinically relevant fungal pathogens that may foster the 
  
development of immunotherapeutic strategies. More recently, the usefulness of Treg-based 
immunotherapeutic approaches in allogeneic transplanted patients has also been 
investigated. Early adoptive therapy with Tregs followed by conventional T cells was 
demonstrated to favor immunologic reconstitution, besides preventing graft-versus-host 
disease without weakening the graft-versus-leukemia effect [20]. However, whether and 
how the adoptive immunotherapy with Tregs may compromise general immunity and blunt 
responses to other infectious agents remain to be fully assessed. 
Anti- inflammatory therapies. Breakthroughs in understanding how immune homeostasis is 
established, maintained or disrupted in the presence of fungal exposure and/or colonization 
could be sources of new therapeutics and drugs targeting specific inflammatory or metabolic 
endpoints. In essence, limiting inflammation to stimulate a protective immune response to 
fungi should pave the way for rational design of novel immunomodulatory therapies. Below 
are examples of new therapeutics potentially capable of simultaneously activating antifungal 
resistance and taming overzealous inflammatory host responses. 
 
PTX3. PTX3 is receiving great attention as a potential therapeutic agent with anti-
inflammatory properties in aspergillosis. PTX3 is an opsonin that forms complexes on the 
conidial surface of A. fumigatus, thereby amplifying the innate immune response. 
Remarkably, PTX3 deficiency renders immunocompetent mice highly susceptible to A. 
fumigatus infection [21], whereas PTX3 administration protected against invasive 
aspergillosis in T cell–depleted allogeneic transplanted mice and potentiated the efficacy of 
amphotericin B. More recently, early administration of exogenous PTX3 was shown to 
enhance the conidiocidal activity of neutrophils and limit the inflammatory pathology in 
NADPH oxidase-deficient mice [22]. Finally, a number of predominantly non-coding 
polymorphisms have been identified in the PTX3 gene which could be relevant in clinical 
fungal infections [23]. 
 
IDO and tryptophan metabolites. It has been shown that resistance and tolerance are two 
types of host defense mechanisms to increase fitness in response to fungi [5]. In experimental 
fungal infections, both defense mechanisms are activated through the delicate equilibrium 
between Th1 cells (which provide anti-fungal resistance mechanisms) and Tregs that limit the 
consequences of the associated inflammatory pathology [24]. IDO and kynurenines pivotally 
contribute to this delicate balance by providing the host with immune mechanisms adequate 
  
for protection without necessarily eliminating fungal pathogens or causing an unacceptable 
level of tissue damage [24]. In their capacity to induce Tregs and inhibit Th17, IDO and 
kynurenines pivotally contribute to cell lineage decision in experimental fungal infections and 
revealed an unexpected potential in the control of inflammation, allergy and Th17-driven 
inflammation in these infections [24]. In this context, the Th17 pathway, which down-
regulates tryptophan catabolism, may instead favor pathology [25] and serves to 
accommodate the seemingly paradoxical association of chronic inflammation with fungal 
disease. In experimental CGD, IL-17 neutralization increased fungal clearance, ameliorated 
inflammatory pathology and restored protective Th1 antifungal resistance [10]. Perhaps more 
importantly, complete cure and reversal of the hyperinflammatory CGD phenotype were 
achieved by administration of supplemental L-kynurenine, an early amino acid catabolite of L-
tryptophan in the IDO-dependent pathway.  
Thymosin α1. Innate signaling may either activate or limit, via induction of Tregs, adaptive 
immunity. This implies that selected PRR ligands might be useful candidate adjuvants to 
dampen inflammatory responses associated with infections. Thymosin α1 (Tα1), a naturally 
occurring thymic peptide, which is approved in 30 countries for treatment of a number of viral 
infections [26] and as an immune adjuvant, has been found to promote maturation of and 
cytokine production by DCs via TLR signaling [27]. By controlling the balance between the 
activity of immunogenic and tolerogenic DCs, Tα1 acted as an endogenous immune regulator 
capable of inducing protective immunity to A. fumigatus. In effect, Tα1 was found to induce 
IDO expression and production of kynurenines, thereby imprinting a tolerogenic program into 
inflammatory DCs [27]. Thus, instructive immunotherapy with Tα1 targeting IDO-competent 
DCs could allow for a balanced control of inflammation and tolerance in aspergillosis. 
Targeting inflammatory pathways by siRNA. The intranasal administration of small 
interfering (si)RNA has opened new avenues in drug delivery and respiratory therapy [28]. 
Although the in vivo use of siRNA has been limited, they have huge potential as therapeutic 
agent given the absence of adverse immune reactions and systemic access. Adding to the 
potential of siRNA as therapeutic agents in the areas of cancer and viral infections, a recent 
study showed the potential of siRNA to attenuate inflammation in respiratory fungal 
infections [29]. In vivo targeting inflammatory (PI3K/Akt/mTOR) or anti-inflammatory 
(STAT3/IDO) pathways by intranasally delivered siRNA modified inflammation and 
immunity in aspergillosis. Thus, the screening of signaling pathways through a systems 
biology approach may be exploited for the development of siRNA therapeutics to attenuate 
  
inflammation in respiratory fungal infections and diseases. Ultimately, because immunity is 
neither simply a set of discrete signaling pathways activated by pathogens nor a function of 
the host, the utilization of systems biology approaches is useful for the generation of new 
therapeutics that targets pathogenicity rather than microbial growth, the host-pathogen 
interface rather than the pathogen and promotes protective immune responses. 
Vaccine development. With the exception of a killed spherule vaccine against 
coccidioidomycosis, no fungal vaccine trials have ever been conducted. However, the level of 
our understanding of fungal−host interactions has progressed to the point where vaccines 
against both primary fungal pathogens and the prevalent opportunistic fungi are becoming a 
reality [30]. In this regard, given the plasticity of the DC system in initiating disparate 
immune responses to fungi, vaccine-induced education of T cells could be regarded as a 
promising strategy to reduce the risk of fungal infection. 
 
Genetic variability and immunotherapy outcome: towards personalized treatments? 
Although the dissection of complex genetic traits modulating susceptibility to fungal 
infections is complex, the contribution of host genetics may hold the key to elucidate genetic 
markers for fungal infections and diseases occurring in high-risk patients. Understanding 
which patients are at highest risk of developing a life-threatening infection is at present a 
major deficiency, and genetic markers will probably assist in risk assessment. A number of 
studies have addressed the role of genetic variability in defining individual susceptibility to 
fungal infections [2-3]. A single nucleotide polymorphism (SNP) in TLR4 was first disclosed 
as a risk factor for chronic aspergillosis in immunocompetent individuals [31] and later, for 
invasive aspergillosis among unrelated allogeneic transplanted patients [32]. More recently, 
the stop codon polymorphism Y238X in dectin-1 was also found to contribute to an increased 
susceptibility to aspergillosis in the stem cell transplantation setting, a study which also 
uncovered the distinct contributions of the hematopoietic/nonhematopoietic cell 
compartments in the induction of immune protection to the fungus [33]. Although 
considerable efforts have been made in this direction, there is still the problem of limited 
power of the existing studies. Larger, well-designed trials, preferably performed in 
consecutive patients, are ultimately required to clarify the usefulness of genetic stratification 
of patients at risk for infection. 
 
  
Perspectives in antifungal immunotherapy 
The new discoveries in the field of fungal immunology have offered new grounds for a better 
comprehension of cells and immune pathways that are amenable to manipulation in patients 
with or at risk of fungal infections (figure 1). By influencing immune responses and 
inflammation, SNPs in immune genes may also affect the outcome of immunotherapeutic 
interventions. Therefore, devising immunotherapeutic strategies should not only consider the 
new conceptual advances on the knowledge of antifungal immunity, but also accommodate 
them from an immunogenetic standpoint. Identifying the cellular and molecular bases affected 
by genetic polymorphisms may prove a very powerful tool, maximizing the potential of 
therapeutic targets and prophylactic strategies exerting control over the outcome of immune 
pathways. Altogether, the genetic screening of at-risk patients may ultimately be used to 
individualize treatments through the formulation of new targeted and patient-tailored 
antifungal immunotherapeutics, likely improving the management and outcome of fungal 
infections. 
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Figure legend 
 
Figure 1. Immunotherapy in aspergillosis. The figure exemplifies recent findings on the 
innate and adaptive immune responses to Aspergillus fumigatus and the possible strategies of 
immune interventions. Most of these immunotherapies have only been evaluated in animal 
models of aspergillosis. PRRs, pattern recognition receptors; EC, epithelial cells; PMN, 
polymorphonuclear cells; Mø, macrophages; Abs, antibodies. See the text for details. 
 
 
 
 
 
 
  
 
